Plasma Glucose Levels As Predictors of Diabetes: the Mexico City Diabetes Study

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2009 Feb 19

PMID 19224196

Citations 14

Authors

E Ferrannini

M Massari

M Nannipieri

A Natali

R Lopez Ridaura

C Gonzales-Villalpando

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: The value of diagnostic categories of glucose intolerance for predicting type 2 diabetes is much debated. We therefore sought to estimate relative and population-attributable risk of different definitions based on fasting (impaired fasting glucose [IFG]) or 2 h plasma glucose concentrations (impaired glucose tolerance [IGT]) and to describe the associated clinical phenotypes.

Methods: We prospectively observed a population-based cohort of 1,963 non-diabetic participants (mean age 47 years), in whom an OGTT was performed at baseline and 7 years later.

Results: IGT was fivefold more prevalent (13.5%) than IFG. In both categories, participants were older, heavier, hyperinsulinaemic, hyperproinsulinaemic and dyslipidaemic compared with participants with normal glucose tolerance. Relative risk of incident diabetes was similar for IFG and IGT categories (3.73 [95% CI: 2.18-6.39] and 4.01 [95% CI: 3.12-5.14], respectively), but the population-attributable risk was fivefold higher for IGT (29% [95% CI: 26-32]) than for IFG (6% [95% CI: 5-7]). Isolated IFG carried no increase in risk. Lowering the threshold to 5.6 mmol/l raised the population-attributable risk of IFG to 23% (95% CI: 20-25); its contribution to diabetes progression, however, was largely due to co-existent IGT. In multivariate analysis adjusting for sex, age, familial diabetes and BMI, fasting and 2 h glucose were independent predictors.

Conclusions/interpretation: Fasting and 2 h glucose values are independent predictors of incident diabetes. Isolated IFG is not a high-risk condition; lowering the diagnostic threshold increases the population-attributable risk of IFG fourfold, but performing an OGTT captures additional diabetes progressors compared with the number identified by IFG.

Citing Articles

Synergistic effects of glucose tolerance and BMI on cardiovascular events and all-cause mortality in a healthy population: CA.ME.LI.A study 7 years follow-up.

Bignotto M, Bianco E, Centofanti L, Russo A, Cas M, Zermiani P Am J Physiol Endocrinol Metab. 2024; 327(4):E498-E511.

PMID: 39196799 PMC: 11482241. DOI: 10.1152/ajpendo.00181.2024.

Review of methods for detecting glycemic disorders.

Bergman M, Abdul-Ghani M, DeFronzo R, Manco M, Sesti G, Fiorentino T Diabetes Res Clin Pract. 2020; 165:108233.

PMID: 32497744 PMC: 7977482. DOI: 10.1016/j.diabres.2020.108233.

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Richter B, Hemmingsen B, Metzendorf M, Takwoingi Y Cochrane Database Syst Rev. 2018; 10:CD012661.

PMID: 30371961 PMC: 6516891. DOI: 10.1002/14651858.CD012661.pub2.

Assessment of the link between in utero exposure to 2-aminoanthracene (2AA) and type-1 diabetes (T1D).

Mays C, Hunter D, Yau W, Gato W J Diabetes Metab Disord. 2017; 16:5.

PMID: 28149833 PMC: 5273839. DOI: 10.1186/s40200-017-0286-6.

Detecting prediabetes among Hispanics/Latinos from diverse heritage groups: Does the test matter? Findings from the Hispanic Community Health Study/Study of Latinos.

Aviles-Santa M, Perez C, Schneiderman N, Savage P, Kaplan R, Teng Y Prev Med. 2016; 95:110-118.

PMID: 27956225 PMC: 5290333. DOI: 10.1016/j.ypmed.2016.12.009.

References

Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A . Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia. 2003; 46(9):1211-9. DOI: 10.1007/s00125-003-1169-6. View

Colagiuri S, Borch-Johnsen K, Wareham N . Back to the future--do IGT and IFG have value as clinical entities?. Diabetes Res Clin Pract. 2008; 81(2):131-3. DOI: 10.1016/j.diabres.2008.07.001. View

. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2002; 23 Suppl 1:S4-19. View

Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner S . Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care. 2005; 28(7):1757-62. DOI: 10.2337/diacare.28.7.1757. View

. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001; 161(3):397-405. DOI: 10.1001/archinte.161.3.397. View

de Vegt F, Dekker J, Jager A, Hienkens E, Kostense P, Stehouwer C . Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA. 2001; 285(16):2109-13. DOI: 10.1001/jama.285.16.2109. View

Nathan D, Davidson M, DeFronzo R, Heine R, Henry R, Pratley R . Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007; 30(3):753-9. DOI: 10.2337/dc07-9920. View

Genuth S, Alberti K, Bennett P, Buse J, DeFronzo R, Kahn R . Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26(11):3160-7. DOI: 10.2337/diacare.26.11.3160. View

Stratton I, Adler A, Neil H, Matthews D, Manley S, Cull C . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMC: 27454. DOI: 10.1136/bmj.321.7258.405. View

10.

Jeppesen J, Facchini F, Reaven G . Individuals with high total cholesterol/HDL cholesterol ratios are insulin resistant. J Intern Med. 1998; 243(4):293-8. DOI: 10.1046/j.1365-2796.1998.00301.x. View

11.

Porte Jr D, Kahn S . Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction?. Diabetes. 1989; 38(11):1333-6. DOI: 10.2337/diab.38.11.1333. View

12.

Natali A, Toschi E, Camastra S, Gastaldelli A, Groop L, Ferrannini E . Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. European Group for the Study of Insulin Resistance (EGIR). Diabetologia. 2000; 43(10):1266-72. DOI: 10.1007/s001250051522. View

13.

Ferrannini E, Nannipieri M, Williams K, Gonzales C, Haffner S, Stern M . Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes. 2003; 53(1):160-5. DOI: 10.2337/diabetes.53.1.160. View

14.

Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo R . beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2004; 90(1):493-500. DOI: 10.1210/jc.2004-1133. View

15.

Unwin N, Shaw J, Zimmet P, Alberti K . Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002; 19(9):708-23. DOI: 10.1046/j.1464-5491.2002.00835.x. View

16.

Pankow J, Kwan D, Duncan B, Schmidt M, Couper D, Golden S . Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. Diabetes Care. 2007; 30(2):325-31. DOI: 10.2337/dc06-1457. View

17.

Rasmussen S, Glumer C, Sandbaek A, Lauritzen T, Borch-Johnsen K . Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark. Diabetologia. 2007; 51(2):249-57. DOI: 10.1007/s00125-007-0893-8. View

18.

Abdul-Ghani M, Williams K, DeFronzo R, Stern M . Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care. 2006; 29(7):1613-8. DOI: 10.2337/dc05-1711. View

19.

Forouhi N, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, Qiao Q . The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia. 2006; 49(5):822-7. DOI: 10.1007/s00125-006-0189-4. View